Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Some Tumors Found to Contain Factors that May Suppress Metastasis

By BiotechDaily International staff writers
Posted on 29 Nov 2011
Scientists are closer to determining what drives tumor metastasis, as laboratory mice models suggest there are factors inside tumors that can inhibit their own growth.

In the November 15, 2011, issue of the Cancer Research, a journal of the American Association for Cancer Research (AACR), Raúl A. Ruggiero, PhD, a biologic researcher at the division of experimental medicine at the National Academy of Medicine in Buenos Aires, Argentina, described this innovative process.

Dr. Ruggiero and colleagues used bioanalytic techniques of ion electrospray mass and tandem mass spectrometry to identify the aspects that lead to metastasis resistance in laboratory models of localized cancer, a phenomenon called “concomitant tumor resistance” in which factors in a tumor can inhibit its own metastasis. “The main cause of death in cancer patients is associated much more with metastasis rather than with the growth of a localized tumor, which generally can be surgically removed,” he said.

Dr. Ruggiero’s laboratory found that the presence of variant forms of the amino acid tyrosine were responsible for concomitant tumor resistance. In tumor models where these variants of tyrosine were present, the localized tumor did not tend to metastasize as fast as tumors lacking the variants.

Currently, tumor metastasis is treated with a variety of chemotherapy regimens, but Dr. Ruggiero said the results of this sort of treatment are usually disappointing. He hopes that these tyrosine variants could be developed as a simple and safe type of therapy to block metastatic growth. “Both meta- and ortho-tyrosine have many attractive features. They exert antitumor effects at very low concentrations, are naturally produced in the proper tumor-bearing organism, and do not appear to exert any toxic side effects,” remarked Dr. Ruggiero. “If these findings are confirmed, we could develop new and more harmless means to manage malignant disease.”

Related Links:
American Association for Cancer Research



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.